#1 Clinical Trials Search in Europe
EU – Europe
AT – Austria
HR – Croatia
CZ – Czech Republic
DK – Denmark
EE – Estonia
FI – Finland
FR – France
DE – Germany
IS – Iceland
IT – Italy
LV – Latvia
LT – Lithuania
NL – Netherlands
NO – Norway
PL – Poland
PT – Portugal
RO – Romania
SK – Slovakia
SI – Slovenia
ES – Spain
SE – Sweden
  • Find a Clinical Trial

    Search Trials by Disease

    Non-small cell lung cancer Breast cancer Plasma cell myeloma Neoplasm Neoplasm malignant Acute myeloid leukaemia Colitis ulcerative Obesity Colorectal cancer metastatic Prostate cancer Crohn's disease Colorectal cancer Dementia Alzheimer's type Ovarian cancer Hepatocellular carcinoma Breast cancer metastatic Dermatitis atopic Asthma Non-small cell lung cancer metastatic Malignant melanoma More trials…
  • Rare Diseases Treatments

    Search Trials by Disease

    Anaemia Primary hyperoxaluria Soft tissue necrosis Thromboangiitis obliterans Stargardt's disease Essential thrombocythaemia IPEX syndrome Gastric cancer Glomerulonephritis Hydrocephalus Richter's syndrome Myeloid leukaemia Parkinson's disease Solitary fibrous tumour Sjogren's syndrome More trials…

    Learn about Rare Diseases

    Encephalitis autoimmune Optic glioma – Diagnostics Progressive multifocal leukoencephalopathy – Life with Disease Sarcoma – Life with Disease Activated PI3 kinase delta syndrome – Treatment Breast angiosarcoma – Basic Information Systemic sclerosis pulmonary – Diagnostics Angiosarcoma recurrent – Treatment Chordoma – Basic Information Mucopolysaccharidosis III – Basic Information More diseases
  • Vaccine Clinical Trials
  • Pediatric Clinical Trials
  • Resources for Patients

    Browse Innovative Treatments

    Ethanol (96 Per Cent) Felzartamab SODIUM SELENITE PENTAHYDRATE Anhydrous Glucose Bp Methotrexate Disodium Ceftolozane Gindameran Berzosertib Psma-11 Gimeracil Satralizumab Sulodexide Gilteritinib GSK5733584 ZINC Sabatolimab Cyanocobalamin Deucrictibant Secukinumab Fluoroestradiol F-18 More therapies…

    Learn about Your Condition

    Salivary gland cancer Hypotonia Coronary artery dissection Marginal zone lymphoma C3 glomerulopathy Basal cell carcinoma Tendon rupture Aortic disorder Delayed graft function Lymphangiosarcoma Cachexia Substance use disorder Iron deficiency anaemia Cirrhosis alcoholic Pemphigus More diseases
  • Healthy Volunteers
  • Patient Guide
  • Our Partners
  • About Us
  • Contact us
  • Region
    🇪🇺 Europe
    🇦🇹 Austria
    🇭🇷 Croatia
    🇨🇿 Czech Republic
    🇩🇰 Denmark
    🇪🇪 Estonia
    🇫🇮 Finland
    🇫🇷 France
    🇩🇪 Germany
    🇮🇸 Iceland
    🇮🇹 Italy
    🇱🇻 Latvia
    🇱🇹 Lithuania
    🇳🇱 Netherlands
    🇳🇴 Norway
    🇵🇱 Poland
    🇵🇹 Portugal
    🇷🇴 Romania
    🇸🇰 Slovakia
    🇸🇮 Slovenia
    🇪🇸 Spain
    🇸🇪 Sweden

Systemic lupus erythematosus

  • Study on the Effects of Upadacitinib in Adults with Moderate to Severe Systemic Lupus Erythematosus (SLE)

    Not recruiting

    3 1
    Investigated Drugs:
    • Upadacitinib
    Belgium Bulgaria Croatia Estonia France Germany +10

  • Study of GLPG3667 for Adults with Active Systemic Lupus Erythematosus

    Not recruiting

    2 1 1
    Investigated Diseases:
    • Systemic lupus erythematosus
    Investigated Drugs:
    • Glpg3667 Fumarate
    Bulgaria France Germany Hungary Poland Spain

  • Study on Frexalimab for Treating Active Systemic Lupus Erythematosus in Patients

    Not recruiting

    2 1
    Investigated Diseases:
    • Systemic lupus erythematosus
    Investigated Drugs:
    • Frexalimab
    Greece Hungary Italy Spain

  • Study on the Effectiveness and Safety of Deucravacitinib for Patients with Active Systemic Lupus Erythematosus (SLE)

    Not recruiting

    3 1 1
    Investigated Diseases:
    • Systemic lupus erythematosus
    Investigated Drugs:
    • Deucravacitinib
    Bulgaria France Germany Ireland Italy Lithuania +2

  • Study on the Effectiveness and Safety of Deucravacitinib for Patients with Active Systemic Lupus Erythematosus (SLE)

    Not recruiting

    3 1
    Investigated Diseases:
    • Systemic lupus erythematosus
    Investigated Drugs:
    • Deucravacitinib
    Bulgaria Czechia Greece Hungary Poland Portugal +1

  • Study on the Safety and Effectiveness of ESK-001 for Adults with Systemic Lupus Erythematosus

    Not recruiting

    2 1 1
    Investigated Diseases:
    • Systemic lupus erythematosus
    Investigated Drugs:
    • Esk-001
    Bulgaria Croatia Denmark Germany Hungary Poland +2
Previous Page
1 … 7 8 9 10
Next Page

Investigational Drugs in This Location

See which drug candidates are part of clinical trials near you. Click for detailed trial information.

Medical Conditions Being Studied in This Location

Explore diseases currently included in clinical trials near you. Click to view trials and details for each condition.

European Clinical Trials Information Network

The European Clinical Trials Information Network is transforming access to clinical trial information for patients across Europe. By overcoming language barriers, our platform allows everyone, regardless of their native language, to easily find relevant and comprehensible clinical trial data. This innovative service connects patients to cutting-edge treatments, creating a unified European community where health and progress transcend borders.

This service is not affiliated with the European Commission, the EMA, or the official CTIS system. Most information comes from publicly available international clinical-trial registries, supplemented by data from academic centres, national regulators, and commercial sponsors. We aim to keep all content accurate and up to date.

Explore the full ecosystem of clinical research in Europe.

The information provided on this website is mainly derived from international public clinical trial databases (CTIS.eu). In addition, we are including supplementary sources, such as information provided by academic centers and national regulators, as well as information supplied by commercial sponsors (pharmaceutical companies and contract research organizations). We try to ensure that the information provided is accurate and up to date.

Certain content and visual elements on this website have been generated or enhanced using artificial intelligence (AI).

The website is published by:
CTIN POLAND sp. z o.o.
with its registered office in Warsaw,
ul. rtm. Witolda Pileckiego 67/109,
02-781 Warsaw, Poland,
entered in the Register of Entrepreneurs of the National Court Register under KRS number 0001111334,
REGON: 528919042, NIP (Tax ID): 9512598637
Contact us

© 2026 CTIN Poland

Privacy Policy

Terms and Conditions

Contact

For Sites and Sponsors

Clinical Trial Locations

We use cookies

The website uses cookies to ensure the proper functioning of the site and to analyze internet traffic. Some cookies are essential for using the service and do not require consent. You can accept all cookies or use only the essential ones. Data is processed in accordance with our Privacy Policy. You have the right to withdraw your consent, access, rectify, delete, or limit the processing of your data at any time.
Numer nieprawidłowy!
Numer nieprawidłowy!